Viral Conjunctivitis Treatment Using Ranpirnase and/or Amphinase

Abstract

The present specification discloses Ranpirnase and Amphinase, compositions comprising Ranpirnase and/or Amphinase, and methods and uses to treat a viral conjunctivitis, an epidemic keratoconjunctivitis, and/or a pharyngoconjunctival fever, reduce or suppress a level of virus or viral titer, reduce or suppress viral replication, reduce or suppress protein synthesis, reduce or suppress a level of a tRNA, reduce or suppress a level of an inflammation inducing molecule and/or an inflammation inducing prostaglandin, stimulate or enhance a peroxisome proliferator-activated receptor (PPAR) pathway signal, promote the resolving phenotypic change of M1 to M2, modulate Th1 and Th2 cytokines, and/or reduce or suppress a NFκB pathway signal using Ranpirnase, Amphinase or compositions comprising Ranpirnase and/or Amphinase.

1 . A method of treating a viral conjunctivitis cause by an adenovirus in an individual in need thereof, the method comprising administering to a surface of a conjunctiva and/or eye of the individual an ophthalmic composition comprising a therapeutic effective amount of at most 6 μg of one or more Ranpirnases,
 wherein administration reduces a symptom associated with the viral conjunctivitis, thereby treating the individual. 
 
     
     
         2 . The method according to  claim 1 , wherein the viral conjunctivitis is an epidemic keratoconjunctivitis, a pharyngoconjunctival fever, a nonspecific sporadic follicular conjunctivitis, or a chronic papillary conjunctivitis. 
     
     
         3 . The method according to  claim 1 , wherein the adenovirus is a Human adenovirus B, a Human adenovirus D, a Human adenovirus E, or any combination thereof. 
     
     
         4 . The method according to  claim 3 , wherein the Human adenovirus B is a Human adenovirus B serotype 3, a Human adenovirus B serotype 7, a Human adenovirus B serotype 11, or any combination thereof. 
     
     
         5 . The method according to  claim 3 , wherein the Human adenovirus D is a Human adenovirus D serotype 8, a Human adenovirus D serotype 13, a Human adenovirus D serotype 19, a Human adenovirus D serotype 37, or any combination thereof. 
     
     
         6 . The method according to  claim 3 , wherein the Human adenovirus E is a Human adenovirus E serotype 4. 
     
     
         7 . The method according to  claim 1 , wherein the adenovirus is Human adenovirus B serotype 3, Human adenovirus E serotype 4, Human adenovirus B serotype 7, Human adenovirus D serotype 8, Human adenovirus B serotype 11, Human adenovirus D serotype 13, Human adenovirus D serotype 19 or Human adenovirus D serotype 37, or any combination thereof. 
     
     
         8 . The method according to  claim 1 , wherein administration of the one or more Ranpirnase has an antiviral activity that reduces or suppresses a level of virus or viral titer in an individual. 
     
     
         9 . The method according to  claim 1 , wherein administration of the one or more Ranpirnase has an antiviral activity that reduces or suppresses viral replication. 
     
     
         10 . The method according to  claim 1 , wherein administration of the one or more Ranpirnase has an antiviral activity that reduces or suppresses protein synthesis in one or more cells of an individual. 
     
     
         11 . The method according to  claim 1 , wherein administration of the one or more Ranpirnase has an antiviral activity that reduces or suppresses a level of tRNA in one or more cells of an individual. 
     
     
         12 . The method according to  claim 1 , wherein the ophthalmic composition further comprises one or more pharmaceutically-acceptable carriers and optionally one or more pharmaceutically-acceptable components. 
     
     
         13 . The method according to  claim 1 , wherein the ophthalmic composition is a liquid formulation, a colloidal formulation, a semi-solid formulation or a solid formulation. 
     
     
         14 . The method according to  claim 1 , wherein the ophthalmic composition is administered by an ocular instillation, an ocular irrigation, an intraocular injection, an intracorneal injection, intravitreal injection or a subconjunctival injection. 
     
     
         15 . The method according to  claim 1 , wherein the ophthalmic composition is a controlled release delivery platform. 
     
     
         16 . The method or use according to  claim 15 , wherein the controlled release delivery platform is an extended release formulation or a sustained release formulation. 
     
     
         17 . The method according to  claim 1 , wherein the ophthalmic composition is an ocular implant, an ophthalmic implant, a punctal plug, an intraocular implant, an intracorneal implant or a subconjunctival implant. 
     
     
         18 . The method according to  claim 1 , wherein the one or more Ranpirnases have the N-terminus blocked pyroglutamic acid or pyrrolidone carboxylic acid. 
     
     
         19 . The method according to  claim 1 , wherein the one or more Ranpirnase includes SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or any combination thereof. 
     
     
         20 . The method according to  claim 1 , wherein the ophthalmic composition is administered up to eight times a day.